Sales 40.3m (-7% vs. ABGSCe), adj. EBIT 16.7m (ABGSCe 19.
Redeye comments on Freemelt’s Q3 results, which were somewhat softer than expected in terms of sales...
Redeye comments on Fantasma Games’ Q3 results, which came in softer than expected.
NOI increased 21% y-o-y, +2% vs. ABGSCe Value changes -1.
Redeye provides an update on Gasporox after its Q3 2023 report.
During the 2023 Tarpeyo's conversion rate has improved gradually from low levels.
Redeye provides an update on BeammWave following its Q3 2023 report.
Redeye provides an update in relation to Enzymatica’s Q3 2023 report.
Q3 EBITDA of USD 16.4m, in line with ABGSCe But soft production lowers estimates Fair value range re...
NoHo's Q3 EBIT of EUR 8.7m was in line with our estimate but 5% short of Vara consensus expectations...
Redeye retains its positive stance towards Hanza following a solid Q3 report, with the strong margin...
Q3: Paper EBITDA PLN 97m vs. ABGSCe of PLN 65m Paper markets still weak - more cuts needed Fair valu...
Redeye comments on the decision by CMS to decrease the average rate for 2024 under the Hospital Outp...
Redeye ceases its coverage of Alelion following the bankruptcy and delisting of the shares from Nasd...
The Swedish authority exercises an option worth SEK13.
STENOCARE announced on November 6th an updated guidance for 2023 and 2024 as well as sales in Q3-23,...
Redeye makes a slight downward adjustment to its Q3 estimates following some additional data points.
Redeye ger en kort kommentar om försäljningssiffrorna för Leqembi under Q3.
Stark utveckling under kvartalet med ökade hyresintäkter.
